AI Medical Technology: New Swedish clinical study published in the British Journal of Dermatology demonstrates superiority of AI-algorithm guided melanoma diagnosis

Sensitivity and specificity values were 95% and 85%, respectively, and 100% and 93% for invasive melanomas

STOCKHOLM, March 6, 2024 /PRNewswire/ --

Results from a prospective, multicentre, clinical trial published today in the peer-reviewed British Journal of Dermatology

link to article

showed that AI helps significantly improve melanoma detection rates.

The trial, conducted in 37 Swedish primary care facilities was designed to evaluate Dermalyser a smartphone-based diagnostic decision support system empowered by advanced artificial intelligence (AI).

Continue Reading

Preview

来源: PRNewswire

Dermalyser

Preview

来源: PRNewswire

CEO Christoffer Ekström

228 patients examined in primary care and exhibiting skin lesions raising concern for melanomas by the doctor, also underwent an additional assessment using a smartphone equipped with a dermatoscope mounted in front of the camera (Dermalyser). Among 253 lesions of concern identified, 21 proved to be melanomas, with 11 invasive melanomas and 10 melanomas in situ (precancerous melanocytic lesions).

Area Under the Receiver Operating Characteristic (AUROC) curve was generated to evaluate Dermalyser's accuracy in identifying melanomas. For invasive melanomas AUROC was 0.965–0.997, corresponding to a maximum sensitivity and specificity of 100% and 92.6%, respectively. Also including melanomas in situ, AUROC was 0.960 with maximum sensitivity and specificity of 95.2% and 84.5%, respectively.

Magnus Falk, Associate Professor in General Practice and Principal Investigator,

Department of Health, Medicine and Caring Sciences, Linköping University, comments: "The clinical decision support tool evaluated in this investigation showed high diagnostic accuracy when used prospectively on primary care patients, which could add significant clinical value for PCPs in assessing skin lesions to detect melanoma. Additionally, the medical personnel involved in the trial were willing to put a high level of trust in Dermalyser, strongly indicating it can be easily worked into current clinical routines."

Christoffer Ekström, CEO of AI Medical Technology adds: "We believe this trial has decisively proven that using AI can revolutionise melanoma diagnosis. This will save lives and also remove the anxiety and often devasting consequences of false results. The European market is our first priority for Dermalyser, but the recently approved AI-powered device for detecting skin cancer by the FDA has also established a clear regulatory pathway for us and we now accelerate our plans for entering the US market."

For more information, please contact:

Christoffer Ekström, CEO AI Medical Technology

Email: [email protected]

Cell phone: +46704 02 71 01

For more information see

www.aimedtech.com and

https://www.linkedin.com/company/aimedicaltechnology/

Photo - https://mma.prnewswire.com/media/2355078/Dermalyser.jpg

Photo - https://mma.prnewswire.com/media/2355079/CEO_Christoffer_Ekstr_m4.jpg

Logo - https://mma.prnewswire.com/media/2355080/AMT_Logo.jpg

SOURCE AI Medical Technology

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。